IDEATE Medical: New Sterilization Technology to Lower Infection Risk
The mission of IDEATE Medical is to lower the infection risk from the 75 million endoscope procedures conducted in the U.S. each year.
The company has developed an innovative low-temperature sterilization technology for the safe and rapid terminal sterilization of all endoscopic devices for every procedure. Currently, the vast majority of devices are disinfected, but not sterilized between uses. Because bacterial spores and organisms may survive after disinfection, this poses a significant risk of potential infection.
Starting in 2019, members of the St. Louis Arch Angels have provided two rounds of funding to IDEATE Medical and are currently leading a $4 million Series A Preferred round.
“The Arch Angels has been an invaluable asset to our team,” says Bob Mosher, CFO, VP Marketing & Business Development. “Brian Kinman and others have provided key business and financial insights that help guide us.”
Because of Arch Angels investment and support, IDEATE Medical moved its headquarters to St. Louis from Saint-Laurent, Quebec.
IDEATE Medical is following the FDA’s pre-submission process and targeting FDA 510(K) Premarket Notification submissions for medical devices by third quarter 2022.
